International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
Seasonal community-acquired respiratory virus infections in patients with cancer-Epidemiological and clinical overview, an analysis of the multicenter OncoReVir registry.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rüthrich Maria M, Schmitt Timo, Classen Annika Y, Brandt Juliane, Spiekermann Karsten, Doleschal Anna D, Seltmann Alva, Henze Larissa, Panse Jens, Sauer Gabriel, Schmaedel Katharina, Schalk Enrico, Vehreschild Maria J G T, Vehreschild Jörg J, Teschner Daniel, von Lilienfeld-Toal Marie, Giesen Nicola
Аннотация
INTRODUCTION: Community-acquired respiratory viruses (CARV) can cause severe infections in patients with cancer. To characterize epidemiology and outcome, the multicenter registry OncoReVir was established in November 2018.
PATIENTS AND METHODS: From November 2018 to October 2024, 2080 patients with cancer and CARV infection were enrolled. Only patients with a single CARV infection were analyzed (n = 1975). Data included demographics, cancer characteristics, and clinical course. A subgroup (n = 381) compared epidemiology and outcome across pre-, peri-, and postpandemic periods. Predefined endpoints were pneumonia, ICU admission, and infection-related mortality.
RESULTS: Median age was 61 years (interquartile range 52-69), 42.5% were female, and 85.5% had hematological diseases. Most frequent CARVs were severe acute respiratory coronavirus 2 (SARS-CoV-2) (36%), influenza (22.5%), human parainfluenza virus (hPIV, 12.5%), and respiratory syncytial virus (RSV, 12%). Epidemiology (excluding SARS-CoV-2) shifted by period: prepandemic, influenza predominated (70.5%); pandemic, RSV (31%); postpandemic, RSV (27.5%), and hPIV (25.5%). Overall, 53% patients were hospitalized, 7% required ICU care, pneumonia occurred in 22.5%, and infection-related mortality was 4% (overall mortality 28%). Endpoint occurrence varied minimally across phases. Influenza drove prepandemic severity, whereas other CARVs became relevant during/after the pandemic.
CONCLUSION: CARV epidemiology in patients with cancer changed substantially across pandemic phases, while clinical severity and infection-related mortality remained largely unchanged.
PATIENTS AND METHODS: From November 2018 to October 2024, 2080 patients with cancer and CARV infection were enrolled. Only patients with a single CARV infection were analyzed (n = 1975). Data included demographics, cancer characteristics, and clinical course. A subgroup (n = 381) compared epidemiology and outcome across pre-, peri-, and postpandemic periods. Predefined endpoints were pneumonia, ICU admission, and infection-related mortality.
RESULTS: Median age was 61 years (interquartile range 52-69), 42.5% were female, and 85.5% had hematological diseases. Most frequent CARVs were severe acute respiratory coronavirus 2 (SARS-CoV-2) (36%), influenza (22.5%), human parainfluenza virus (hPIV, 12.5%), and respiratory syncytial virus (RSV, 12%). Epidemiology (excluding SARS-CoV-2) shifted by period: prepandemic, influenza predominated (70.5%); pandemic, RSV (31%); postpandemic, RSV (27.5%), and hPIV (25.5%). Overall, 53% patients were hospitalized, 7% required ICU care, pneumonia occurred in 22.5%, and infection-related mortality was 4% (overall mortality 28%). Endpoint occurrence varied minimally across phases. Influenza drove prepandemic severity, whereas other CARVs became relevant during/after the pandemic.
CONCLUSION: CARV epidemiology in patients with cancer changed substantially across pandemic phases, while clinical severity and infection-related mortality remained largely unchanged.